Nanoparticulate Drug Delivery: Perspectives on the Transition from Laboratory to Market

ISBN-13: 9781907568985 / Angielski / Twarda / 2012 / 244 str.

Vandana Patravale; Prajakta Dandekar; Ratnesh Jain

Opis

Nanotechnology-based therapeutics, operating at scales of billionths of a metre, have great potential for future expansion in altering the scale and methods of drug delivery. The availability of these novel formulations to once-inaccessible areas of the body has greatly expanded the therapeutic window of existing drug molecules. Nanoparticulate drug delivery highlights and examines the transition of nanoparticulate drug delivery systems from the laboratory into a commercially viable sector. The first chapters of the book provide an overview of the use and characterization of nanoparticulate systems as drug carriers, including the assessment of their morphology, sterility and potential toxicity. In the latter part of the book, chapters cover nanotoxicology, regulatory aspect and clinical trials, ending with an overview of several case studies and a look towards future developments.

• Discusses the issues surrounding nanoparticulate products, based on personal experience of their formulation
• Provides an overview of new application areas, including RNA interference
• Outlines the pros and cons of nanoparticulate products, and discusses how these may influence their route into the commercial sector

Spis treści

List of figures

List of tables

Foreword

Chapter 1: Nanoparticulate systems as drug carriers: the need

Abstract:

1.1 Introduction: nanoparticles for drug delivery

1.2 Need: solubility, bioavailability, targeting and more

1.3 Specific nanoparticulate strategies for overcoming solubility and bioavailability limitations

Chapter 2: Nanoparticles as drug carriers

Abstract:

2.1 Nanoparticles as drug carriers: the scope

2.2 Nanoparticles as drug delivery carriers

2.3 Application areas for nanoparticulate drug delivery systems

2.4 Routes of administration of nanoparticulate drug delivery systems

2.5 Conclusion

Chapter 3: Characterization techniques for nanoparticulate carriers

Abstract:

3.1 Need and challenges for characterization techniques of nanoparticulate drug carriers

3.2 Measuring the size of nanoparticles

3.3 Zeta potential measurement [1, 4]

3.4 Characterizing the morphology of the nanoparticles

3.5 Assessing the sterility and detecting mycoplasma or microbial contamination of nanoparticles [46, 47]

3.6 Toxicity evaluation of nanoparticles

3.7 Evaluating immunological potential of nanoparticles

Chapter 4: Nanotoxicology: evaluating toxicity potential of drug-nanoparticles

Abstract:

4.1 Nanotoxicology: need towards developing safe and sustainable drug delivery systems

4.2 In vitro assays for assessing toxicity of nanoparticles

4.3 In-vivo assays for assessing toxicity of nanoparticles

4.4 Genotoxicity evaluation

Chapter 5: Regulatory aspects of nanoparticulate drug delivery systems

Abstract:

5.1 Nanoparticulate drug carriers: the regulatory facet

5.2 Issues associated with regulating nano-drug delivery systems

5.3 Current approaches for regulating pharmaceutical nanocarriers

Chapter 6: Clinical trials industrial aspects

Abstract:

6.1 Clinical trials of nanoparticulate drug delivery systems: successes and failures

6.2 Case studies: cancer

6.3 Case studies: other diseases

6.4 Nanoparticulate drug delivery: an industrial outlook

Chapter 7: Case studies: nano-systems in the market

Abstract:

7.1 Case studies: performance and market approval

7.2 Are nano or conventional drug delivery systems a better choice? - a market overview

7.3 Future perspectives on nanoparticulate drug carriers

Index